KNSA Projected Dividend Yield
Cl A Ord/Kiniksa Pharmaceuticals International plc ( NASDAQ : KNSA )Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. Co. is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. Co.'s ARCALYST is interleukin-1alpha (IL-1?), and interleukin-1beta (IL-1?), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. 21 YEAR PERFORMANCE RESULTS |
KNSA Dividend History Detail KNSA Dividend News KNSA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |